{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:58:11Z","timestamp":1793217491448,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Subacute sclerosing panencephalitis (SSPE) is a slow virus infectious disease resulting from persistent infection with mutant measles virus. At present, there is no effective treatment for SSPE. Interferon-\u03b1 and inosine pranobex have both been used for the treatment of SSPE, and partial success has been reported for the antiviral drug, ribavirin (RBV). The standardization of dosage method is necessary to carry out treatment with RBV more safely and effectively. In this study, RBV concentrations in cerebrospinal fluid (CSF) were monitored during the intraventricular administration using a subcutaneous continuous infusion pump.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Three patients with new-onset SSPE were treated with RBV using a subcutaneous continuous infusion pump. On days 3\u201310 after the start of RBV infusion, CSFs were obtained by lumbar tap, and the concentration of RBV in the CSF was measured using high-performance liquid chromatography.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>RBV concentration increased in a dose-dependent manner in all 3 patients, and the target concentration could be generally maintained without any severe side effects. We observed that the clinical symptoms were temporarily relieved in each case. In the 2 cases for whom treatment is continuing, the patients remain in stage III, while the patient who discontinued the therapy progressed to stage IV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The target RBV concentration in the CSF could be maintained continuously by intraventricular administration using a subcutaneous continuous infusion pump. The accumulation of further cases is necessary to confirm the safety and efficacy of this medical treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002181","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T23:52:35Z","timestamp":1535586755000},"page":"496-499","source":"Crossref","is-referenced-by-count":15,"title":["Maintaining Concentration of Ribavirin in Cerebrospinal Fluid by a New Dosage Method; 3 Cases of Subacute Sclerosing Panencephalitis Treated Using a Subcutaneous Continuous Infusion Pump"],"prefix":"10.1097","volume":"38","author":[{"given":"Kyohei","family":"Miyazaki","sequence":"first","affiliation":[{"name":"From the Department of Pediatrics, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Suyama","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoki","family":"Sato","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusaku","family":"Abe","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuto","family":"Kanno","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Maeda","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Hosoya","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/B978-0-444-52910-7.00039-8","article-title":"Subacute sclerosing panencephalitis and chronic viral encephalitis.","volume":"112","author":"Anlar","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1177\/0883073811436250","article-title":"Survey of subacute sclerosing panencephalitis in Japan.","volume":"27","author":"Abe","year":"2012","journal-title":"J Child Neurol"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/ije\/dym207","article-title":"Review of the effect of measles vaccination on the epidemiology of SSPE.","volume":"36","author":"Campbell","year":"2007","journal-title":"Int J Epidemiol"},{"issue":"3 Pt 1","key":"R4-20230912","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1212\/WNL.42.3.488","article-title":"Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis.","volume":"42","author":"Yalaz","year":"1992","journal-title":"Neurology"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0387-7604(93)90120-W","article-title":"Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis.","volume":"15","author":"Gascon","year":"1993","journal-title":"Brain Dev"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/088307380301801201","article-title":"Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study.","volume":"18","author":"Gascon","year":"2003","journal-title":"J Child Neurol"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/hep.26421","article-title":"Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.","volume":"58","author":"Mori","year":"2013","journal-title":"Hepatology"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0166-3542(89)90072-7","article-title":"Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication in vitro.","volume":"12","author":"Hosoya","year":"1989","journal-title":"Antiviral Res"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1128\/AAC.38.4.653","article-title":"Effect of ribavirin on subacute sclerosing panencephalitis virus infections in hamsters.","volume":"38","author":"Honda","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1128\/AAC.48.12.4631-4635.2004","article-title":"Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis.","volume":"48","author":"Hosoya","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/088307380201700911","article-title":"Treatment of subacute sclerosing panencephalitis with interferon-alpha, ribavirin, and inosiplex.","volume":"17","author":"Solomon","year":"2002","journal-title":"J Child Neurol"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0387-7604(03)00062-7","article-title":"Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis in Japan.","volume":"25","author":"Tomoda","year":"2003","journal-title":"Brain Dev"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s12028-011-9669-6","article-title":"Accidental intoxication with 60\u2009mg intrathecal baclofen: survived.","volume":"16","author":"Berger","year":"2012","journal-title":"Neurocrit Care"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/infdis\/159.4.748","article-title":"Oral ribavirin therapy for subacute sclerosing panencephalitis.","volume":"159","author":"Ogle","year":"1989","journal-title":"J Infect Dis"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.45.3.943-945.2001","article-title":"High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis.","volume":"45","author":"Hosoya","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-20230912","first-page":"224","article-title":"[Serious complications of intraventricular interferon-alpha and ribavirin in the treatment of subacute sclerosing panencephalitis].","volume":"41","author":"Sato","year":"2009","journal-title":"No To Hattatsu"},{"issue":"Suppl 7","key":"R17-20230912","first-page":"S198","article-title":"Subacute sclerosing panencephalitis in immunized Thai children.","volume":"94","author":"Khusiwilai","year":"2011","journal-title":"J Med Assoc Thai"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201905000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:24:12Z","timestamp":1694557452000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201905000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002181","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}